The Induction of Ovulation by Tamoxifen

Williamson, J.; Ellis, J. D.

doi:10.1111/j.1471-0528.1973.tb11230.x

Cited by 105 publications

(49 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results were similar to those reported by Williamson and Ellis (1973) and Tajima et al (1977) and the time lag was between day 13 and 46 of the treatment, i.e. 22.5+ 1.4 on average, demonstrating a wider distribution.…”

Section: Discussionsupporting

confidence: 81%

“…Treatment with 60 mg daily was considered necessary in order to induce satisfactory rates of ovulation in the patients of the first grade amenorrhea. According to Williamson and Ellis (1973) who investigated the relationship between the dosage level and the ovulation inducing rate, 20 mgdaily recorded a ovulatory response rate of 61.9%, 40 mg-daily did 60 and 80 mg-daily did 80%. When taking their results into account, tamoxifen might be administered at dosage level as high as 80 mg/daily, but at the same time, great cautions should be exercised on manifestation of adverse reactions.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Induction of ovulation with an estrogen antagonist, tamoxifen.

Tsuiki¹,

Uehara²,

Kyono³

et al. 1984

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Tamoxifen (Norvadex®), synthesized by the Imperial Chemical Industries Ltd., is a triphenylethylene derivative having a clomiphene-like structure and displays antiestrogenic activities. In this study we used tamoxifen for the treatment of anovulatory infertility and investigated the clinical results. Induction rate of ovulation recorded 100% in the patients with sporadic anovulatory cycle, 83.3% in those with persistent anovulatory cycle, 70% in those with the first grade amenorrhea type I and 66.7% in those with the first grade amenorrhea type II. However, tamoxifen was absolutely ineffective against the second grade amenorrhea. The patients with sporadic or persistent anovulatory cycle responded to 40 mg-daily tamoxifen-treatment, recording 100% of ovulatory induction rate. The patients with the first grade amenorrhea also responded to 60 mg-daily treatment, indicating 70% of ovulatory induction rate. The rate of pregnancy established in the women desiring pregnancy marked 15.4%, and 2 out of 4 women with successful pregnancy experienced spontaneous abortion. Out of 4 patients who did not respond to the previous clomiphene treatment, 3 women accomplished ovulatory induction with tamoxifen. The endocrinological dynamics in the tamoxifen treatment were similar to those in the clomiphene treatment.tamoxifen ; anovulatory infertility ; induction of ovulation ; clomiphene Among infertile women due to ovulatory disturbance, those with anovulatory cycle and the first grade amenorrhea showing withdrawal bleeding in response to injection of progesterone are generally treated with clomiphene citrate (Clomid®), as the first choice drug for induction of ovulation. In contrast to its high rate of induction of ovulation, however, clomiphene citrate marks only a low figure in pregnancy achievement. This is presumably attributed to the insufficiency in cervical mucus secretion, luteal phase deficiency following established ovulation, those which originate in the antiestrogenic activity of this agent. Furthermore, it is known that among the patients with anovulatory cycle and the first grade amenorrhea, about 25-30 per cent of cases do not respond to several cycles of

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Induction of ovulation with an estrogen antagonist, tamoxifen.

Tsuiki¹,

Uehara²,

Kyono³

et al. 1984

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Williamson et al reported an ovulation rate of 81% whereas another study by Messinis et al reported the ovulation rate as 76.08% while using tamoxifen for ovulation induction. 7,12 The pregnancy rates as seen in our study were found to be similar to those reported by Williamson et al and Fukushima et al,(35.5%) with the use of tamoxifen in cases of luteal phase defects. In patients of PCOS Gulekli et al reported an ovulation rate of 70% whereas Seyedoshohadaei F et al reported ovulation rate of 68% and pregnancy rate of 40%.…”

supporting

confidence: 80%

“…It is primarily used as an adjuvant therapy in the treatment of breast cancer but its use as an ovulatory agent was first reported in 1973. 7 Unlike clomiphene, tamoxifen acts as an agonist on the estrogen receptors of the vaginal mucosa and endometrium but studies on the effects of tamoxifen on cervical mucus have been inconclusive. Also there are no reports of increased chances of ovarian cancer with use of tamoxifen.…”

Section: Introductionmentioning

confidence: 99%

Comparison between tamoxifen and clomiphene citrate for induction of ovulation and successful conception in polycystic ovarian syndrome

Hassan

2015

Int J Reprod Contracept Obstet Gynecol

View full text Add to dashboard Cite

“…The drug was found to be an extremely potent postcoital contraceptive in the rat [4,5]. Unfortunately, ICI 46,474 did not exhibit antifertility properties in women, in fact, quite the opposite, it induced ovulation [6,7]. As a result, the medicine was, at one time, marketed in the United Kingdom for the induction of ovulation in subfertile women with a functional hypothalamo-pituitary-ovarian axis.…”

Section: Tamoxifen the First Sermmentioning

confidence: 99%

New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer

2007

View full text Add to dashboard Cite

The metabolism of tamoxifen is being redefined in the light of several important pharmacological observations. Recent studies have identified 4-hydroxy N-desmethyl tamoxifen (endoxifen) as an important metabolite of tamoxifen necessary for antitumor actions. The metabolite is formed through the enzymatic product of CYP2D6 which also interacts with specific selective serotonin reuptake inhibitors (SSRIs) used to prevent the hot flashes observed in up to 45% of patients taking tamoxifen. Additionally, the finding that enzyme variants of CYP2D6 do not promote the metabolism of tamoxifen to endoxifen means that significant numbers of women might not receive optimal benefit from tamoxifen treatment. Clearly these are particularly important issues not only for breast cancer treatment but also for selecting premenopausal women, at high risk for breast cancer, as candidates for chemoprevention using tamoxifen.

show abstract

The Induction of Ovulation by Tamoxifen

Cited by 105 publications

References 3 publications

Induction of ovulation with an estrogen antagonist, tamoxifen.

Induction of ovulation with an estrogen antagonist, tamoxifen.

Comparison between tamoxifen and clomiphene citrate for induction of ovulation and successful conception in polycystic ovarian syndrome

New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer

Contact Info

Product

Resources

About